Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD) (IMPAEPOC)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01266395
First received: December 21, 2010
Last updated: August 8, 2011
Last verified: August 2011
  Purpose

Observational study to know the Impact of morning symptoms in clinical control of COPD patients. 1200 patients will be included by General practitioners (GPs) and pneumologists. Objective: establish if there are differences in the impact of COPD on daily activities and morning symptoms measured through questionnaires of daily life activity (Capacity of Daily Living during the Morning (CDLM), Global Chest Symptoms Questionnaire (GCSQ))


Condition
COPD

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Impact of Morning Symptoms in Clinical Control of COPD

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Determine if there are differences in the impact of COPD on patients according to the characteristics of the disease. To measure the impact of specific self-administered questionnaires used in COPD: CDLMQ, GCSQ and CCQ [ Time Frame: Retrospective, (previous 24 months) ] [ Designated as safety issue: No ]
    Capacity of Daily Living during the Morning Qustionnaire (CDLMQ), Global Chest Symptoms Questionnaire (GCSQ)and COPD Control Questionnaire (CCQ)


Secondary Outcome Measures:
  • Assess comorbidities as a risk factor for frequent exacerbations [ Time Frame: Retrospective, (previous 24 months) ] [ Designated as safety issue: No ]

Enrollment: 1268
Study Start Date: January 2010
Study Completion Date: July 2011
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

General Practitioners and pneumologist

Criteria

Inclusion Criteria:

  • Patient has signed informed consent form
  • Patients of both sexes,> 40 years.
  • Patients diagnosed with COPD according to global consensus on the definition, classification and management of the disease (GOLD) criteria:

    • post-bronchodilator forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) <70%
    • post-bronchodilator FEV1 <80% (stage II, III and IV)

Exclusion Criteria:

  • Participating in an epidemiological study or clinical trial
  • Patient with other respiratory disease than COPD (eg bronchial asthma, cystic fibrosis, severe bronchiectasis, restrictive lung disease, cancer, etc.).
  • Patients with mild COPD: FEV1> 80%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01266395

  Hide Study Locations
Locations
Spain
Research Site
Vitoria, Alava, Spain
Research Site
Elda, Alicante, Spain
Research Site
Petrer, Alicante, Spain
Research Site
Arriondas, Asturias, Spain
Research Site
Cangas de Narcea, Asturias, Spain
Research Site
Jarrio, Asturias, Spain
Research Site
Oviedo, Asturias, Spain
Research Site
El Hospitalet de Llobregat, Barcelona, Spain
Research Site
Puerto Real, CAdiz, Spain
Research Site
Castellon de La Plana, Castellon, Spain
Research Site
Torreblanca, Castellon, Spain
Research Site
Vinaros, Castellon, Spain
Research Site
Lucena, Cordoba, Spain
Research Site
Pea'arroya-pueblonuevo, Cordoba, Spain
Research Site
A Picota (mazaricos), Coruna, Spain
Research Site
Carballo (carballo), Coruna, Spain
Research Site
Ferrol, Coruna, Spain
Research Site
Santiago de Compostela, Coruna, Spain
Research Site
Placencia de Las Armas-soraluz, Guipuzcoa, Spain
Research Site
San Sebastian, Guipuzcoa, Spain
Research Site
Inca, Illes Balears, Spain
Research Site
Son Ferriol, Illes Balears, Spain
Research Site
Espeluy, Jaen, Spain
Research Site
Mures, Jaen, Spain
Research Site
Najera, La Rioja, Spain
Research Site
Arguineguin, Las Palmas, Spain
Research Site
Abadin (casco Urbano), Lugo, Spain
Research Site
Baralla (casco Urbano), Lugo, Spain
Research Site
Viveiro (casco Urbano), Lugo, Spain
Research Site
Alcala de Henares, Madrid, Spain
Research Site
Alcorcon, Madrid, Spain
Research Site
San Sebastian de Los Reyes, Madrid, Spain
Research Site
Cieza, Murcia, Spain
Research Site
Pamplona, Navarra, Spain
Research Site
Leiro (capital), Ourense, Spain
Research Site
Vigo, Pontevedra, Spain
Research Site
Dos Hermanas, Sevilla, Spain
Research Site
Villanueva Del Ariscal, Sevilla, Spain
Research Site
Benaguasil, Valencia, Spain
Research Site
Burjassot, Valencia, Spain
Research Site
La Pobla de Vallbona, Valencia, Spain
Research Site
Almeria, Spain
Research Site
Avila, Spain
Research Site
Badajoz, Spain
Research Site
Barcelona, Spain
Research Site
Guadalajara, Spain
Research Site
Lugo, Spain
Research Site
Madrid, Spain
Research Site
Murcia, Spain
Research Site
Sevilla, Spain
Research Site
Valencia, Spain
Research Site
Zaragoza, Spain
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01266395     History of Changes
Other Study ID Numbers: NIS-RES-DUM-2010/2
Study First Received: December 21, 2010
Last Updated: August 8, 2011
Health Authority: Spain: Ethics Committee, Spanish Agency of Medicines

Keywords provided by AstraZeneca:
morning symptoms COPD

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 18, 2014